DNANUDGE
Consumer genetics testing and medical diagnostics pioneer DnaNudge today announces that it has signed a new major distributor agreement that will speed the commercial roll-out of its breakthrough rapid genetic testing solutions across Spain.
The new strategic partnership with Madrid-based Quirónprevención, grants the experienced distributor the exclusive rights to market and sell DnaNudge’s Nutrition Service, the upcoming DnaNudge Skincare service, and the first ever sample-to-result RT-PCR COVID-19 test (‘CovidNudge’). Quirónprevención is part of Quirónsalud – the leading hospital group in Spain and one of the world’s largest hospital groups. This new distributor signing is part of a significant ramp-up in the next phase of DnaNudge’s commercial growth, following its successful completion of a $60 million Series A investment round led by investment company Ventura Capital. DnaNudge’s first major fund-raising round also included participation from the world’s largest independent wealth manager Bank Julius Baer.
DnaNudge’s portable, clinical-grade point-of-care testing platform – which delivers accurate results in just over an hour, without the need for a laboratory or any manual sample pre-processing – is generating intense commercial interest from healthcare providers, private organisations and government bodies worldwide. DnaNudge has entered into a number of significant wholesale supply agreements, delivering its COVID-19 rapid, lab-free test at scale to major international healthcare companies.
Commenting on the new partnership, Regius (Royal) Professor Chris Toumazou FRS, FREng, FMedSci, CEO and co-founder of DnaNudge and founder of the Institute of Biomedical Engineering at Imperial College London said: “We are delighted to have signed this new strategic agreement with Quirón Prevención, S.L that will dramatically speed availability of our products for businesses and consumers across Spain. Our breakthrough rapid, lab-free COVID-19 test provides a highly accurate and easy-to-use solution that offers crucial reassurance and protection for people and businesses as key sectors of our societies and economies begin to build back. From public and private healthcare providers to corporate customers and the vital travel industry, the global market demand for our solutions is extremely high, and we look forward to announcing further partnerships in the very near future that will enable us to serve this interest worldwide.”
The CE-marked CovidNudge test was adapted in record time last Spring from DnaNudge’s on-the-spot consumer DNA testing service, available at its flagship store in London’s Covent Garden. DnaNudge offers the world’s first service to use consumers’ own DNA plus lifestyle factors to nudge people towards healthier and more personalised choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profiles to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating. The company will shortly be extending its consumer genetics services into personalised skincare shopping. In July, DnaNudge was named the winner of the prestigious Royal Academy of Engineering’s MacRobert Award, the UK's longest-running national prize for engineering innovation.
Capable of a high level of multiplexing, with 72 different testing wells available on a single testing cartridge, the transformative DnaNudge testing platform offers the ability to test simultaneously for all known SARS-CoV-2 virus variants, FluA, FluB, respiratory syncytial virus (RSV), plus markers indicating genetic risk for key health conditions – all on the same test cartridge, from sample direct to result.
Ends---
About DnaNudge (http://www.dnanudge.com )
DnaNudge is the developer of the world’s first service to use consumers’ own DNA plus lifestyle factors to nudge people towards healthier choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profile to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating. The service has been developed by world-renowned biomedical engineer Regius Professor Chris Toumazou FRS and published geneticist Dr Maria Karvela.
This ground-breaking DNA testing service created to address an epidemic – obesity and Type 2 diabetes – has been successfully adapted for the fight against a pandemic, with the development of the rapid, lab-free CovidNudge RT-PCR test. CovidNudge can accurately detect COVID-19 and other viruses in just over an hour, without the need for a laboratory, and is in use in hospitals around the world.
About Quirónprevención
Quirónprevención is the occupational health and safety consulting company part of the Fresenius Group. We take care of our customer's companies ensuring safety in their work centers and the health of the people who work in them. We are currently the leading company in our sector nationally as well internationally, with more than 5 thousand professionals taking care of 190 thousand companies and 4 million workers.
Due to this implantation, Quirónprevención is able to offer a global service, standardizing and adapting the policies of our customers in each of the countries where they operate. Innovation is another mainstay of our corporate identity and the way we work. We are aware that we live in a society that changes and updates at a dizzying speed, in which new generations and new professional profiles are being incorporated. Those we have to reach in order to continue doing our job. This requires a constant renewal and recycling, new format development and new innovative solutions that help us integrate health and safety culture at every level of the company, making attractive content.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom